September 30th, 2016
•Utilizing patient-derived tumors in a subcutaneous preclinical model is an excellent way to study the efficacy of novel therapies, predictive biomarker discovery, and drug resistant pathways. This model, in the drug development process, is essential in determining the fate of many novel anti-cancer therapies prior to clinical investigation.
Tags
Videos relacionados
Labeling of Breast Cancer Patient-derived Xenografts with Traceable Reporters for Tumor Growth and Metastasis Studies
A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
Digital Polymerase Chain Reaction Assay for the Genetic Variation in a Sporadic Familial Adenomatous Polyposis Patient Using the Chip-in-a-tube Format
Investigation of Genetic Dependencies Using CRISPR-Cas9-based Competition Assays
Patient-derived Orthotopic Xenograft Models for Human Urothelial Cell Carcinoma and Colorectal Cancer Tumor Growth and Spontaneous Metastasis
Patient-derived Heterogeneous Xenograft Model of Pancreatic Cancer Using Zebrafish Larvae as Hosts for Comparative Drug Assessment
A Melanoma Patient-Derived Xenograft Model
Establishment of Gastric Cancer Patient-derived Xenograft Models and Primary Cell Lines
ACERCA DE JoVE
Copyright © 2024 MyJoVE Corporation. Todos los derechos reservados